Comparison · NCT00726323-sae
Intermittent 5 & 9 Dosing Regimen vs Daily Dosing Regimen: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intermittent 5 & 9 Dosing Regimen vs Daily Dosing Regimen: serious adverse events. Trial comparisons, record NCT00726323-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00726323-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.541 | 0.384 | 0.69 | wilson | |
| Risk in group 2 | 0.595 | 0.435 | 0.737 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0541 | -0.265 | 0.164 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.909 | 0.61 | 1.35 | log | |
| Odds ratio, group 1 over group 2 | 0.802 | 0.319 | 2.02 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Intermittent 5 & 9 Dosing Regimen than on Daily Dosing Regimen | 18.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intermittent 5 & 9 Dosing Regimen | Eligible participants received oral foretinib bisphosphate 240 mg on Days 1 to 5 of every 14-day cycle. Participants continued this schedule for 8 weeks. The treatment drug was supposed to be stopped any time in case of disease progression. All participants were followed-up every 8 weeks for tumor assessment, while the participant remained in the treatment extension period. | 20 | 37 | EG000 |
| Group 2 | Daily Dosing Regimen | Eligible participants received oral foretinib bisphosphate 80 mg daily of every 14-day cycle. Participants continued this schedule for 8 weeks. treatment drug was supposed to be stopped any time in case of disease progression. All participants were followed-up every 8 weeks for tumor assessment, while the participant remained in the treatment extension period. | 22 | 37 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Approximately up to 48 months
Source ClinicalTrials.gov
Trial
- Title
- A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
- NCT number
- NCT00726323
- Phases
- PHASE2
- Conditions
- Carcinoma, Renal Cell
- Interventions
- foretinib (formerly GSK1363089 or XL880)
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2017-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00726323?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00726323-sae